Chester County News and Community Website
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network is funding four quality-improvement projects aimed at reducing gaps in metastatic prostate cancer care, targeting disparities in access, inconsistent testing and …
NCCN Funds Projects to Close Gaps in Prostate Cancer Care Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration finalized an expedited regulatory pilot that will pair drug companies with qualified research institutions to shorten the path to first-in-human clinical …
FDA Opens Expedited Drug Trial Pilot to Cut Development Delays Read More
WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More WILMINGTON, DE — AstraZeneca’s experimental COPD drug tozorakimab reduced moderate and severe exacerbations by as much as 34% in two Phase III trials across a broad patient population, supporting a …
AstraZeneca COPD Drug Cuts Exacerbations in Phase III Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has dosed the first patient in a Phase 1 trial of CT-202, moving its Nectin-4 x CD3 bispecific antibody into human testing …
Context Therapeutics Starts Phase 1 Trial of CT-202 Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is using clinical data from an investigator-led study to support trans-radial use of its Dynetic-35 stent for treating iliac artery lesions, offering physicians …
Teleflex Study Backs Radial Access for Iliac Stenting Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More